Journal of Research in Pharmacy 2019; 23(5): 952-959
DOI: 10.35333/jrp.2019.42

SUPPLEMENTARY MATERIAL

Class I histone deacetylase inhibition by aryl butenoic acid derivatives: *in silico* and *in vitro* studies

Gamze BORA [1] *, Suat SARI [2], Gülce TAŞKOR [3], Sevim DALKARA [2], Hayat ERDEM-YURTER [1]

1 Department of Medical Biology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

2 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.

3 Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.

* Corresponding Author. E-mail: gamzeb@hacettepe.edu.tr (G.B); Tel. +90-312-305 25 41; Fax. +90-312-309 60 60.

CONTENTS



Figure S1. ^{1}H-NMR spectrum of potassium 4-(4-methoxyphenyl)-2-oxobut-3-enoate (1a)



Figure S2. ^{1}H-NMR spectrum of (*E*)-methyl 4-(4-methoxyphenyl)-2-oxobut-3-enoate (C1)



Figure S3. ^{1}H-NMR spectrum of (*E*)-4-(4-methoxyphenyl)-1-morpholinobut-3-ene-1,2-dione (C3)



Figure S4. ^{1}H-NMR spectrum of (*E*)-1-(2,6-dimethylmorpholino)-4-(4-methoxyphenyl)but-3-ene-1,2-dione (C4)



Figure S5. Docking poses of **C1** (green), **C3** (orange), and **C4** (yellow) in the catalytic site of HDAC2 (A, B, and C, respectively) and HDAC3 (D, E, and F, respectively).